Olympiad Research LP Purchases New Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Olympiad Research LP purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,445 shares of the medical research company’s stock, valued at approximately $267,000.

A number of other large investors have also added to or reduced their stakes in the business. VisionPoint Advisory Group LLC bought a new stake in Charles River Laboratories International in the 4th quarter valued at $1,751,000. Handelsbanken Fonder AB grew its holdings in Charles River Laboratories International by 1.6% in the 4th quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company’s stock valued at $2,296,000 after buying an additional 200 shares in the last quarter. Bryn Mawr Capital Management LLC grew its holdings in Charles River Laboratories International by 1,871.2% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 35,659 shares of the medical research company’s stock valued at $6,583,000 after buying an additional 33,850 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in Charles River Laboratories International by 170.2% in the 4th quarter. Venturi Wealth Management LLC now owns 4,367 shares of the medical research company’s stock valued at $806,000 after buying an additional 2,751 shares in the last quarter. Finally, Empower Advisory Group LLC grew its holdings in Charles River Laboratories International by 2.5% in the 4th quarter. Empower Advisory Group LLC now owns 275,851 shares of the medical research company’s stock valued at $50,922,000 after buying an additional 6,747 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $163.11 on Monday. The stock’s 50-day simple moving average is $172.84 and its 200 day simple moving average is $188.00. The firm has a market capitalization of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year. During the same period last year, the firm posted $2.46 earnings per share. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analysts Set New Price Targets

CRL has been the topic of a number of research reports. Robert W. Baird decreased their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday. Morgan Stanley decreased their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Evercore ISI upped their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. Bank of America decreased their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. Finally, William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $195.71.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster bought 6,075 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares of the company’s stock, valued at $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).